Cellectar Biosciences, Inc.
CLRBNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$23.0M | −$51.8M | −$39.0M | −$28.8M | −$24.1M | −$15.3M |
| Net income | −$21.8M | −$44.6M | −$42.8M | −$28.6M | −$24.1M | −$15.1M |
| Total assets | $15.0M | $25.5M | $12.1M | $21.6M | $37.2M | $58.7M |
| Total liabilities | $5.1M | $9.8M | $25.9M | $6.1M | $4.2M | $3.9M |
| Equity | $8.5M | $14.3M | −$15.2M | $8.2M | $33.0M | $54.8M |
| EPS (diluted) | $-8.35 | $-1.40 | $-3.50 | $-4.05 | $-4.35 | $-1.84 |
| Shares out. | 46.1M | 32.3M | 9.7M | 61.1M | 50.5M | 9.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −255.2%
- Return on assets
- −145.5%
- Return on capital (ROCE)
- −224.7%
- Liabilities / assets
- 33.8%
- Debt / equity
- 0.59×
- Book value / share
- $0.19
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -63.05distress
- Accruals / assets
- 8.9%moderate
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 1 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 13, 2024
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2024
- NT 10-Qmissed a reporting deadline ↗May 18, 2015
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2011
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Active Not Recruitingreadout ~2026-05Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
- Phase 2Active Not Recruitingreadout ~2026-06-22Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
- Phase 1Active Not Recruitingreadout ~2026-08-25Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
- Phase 1Recruitingreadout ~2028-02Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Stonepine Capital Management, LlcPassive (13G)May 11, 2026
- Bleichroeder LpPassive (13G)Feb 13, 2026
- Rosalind Advisors, Inc.Passive (13G)Feb 10, 2026
- Hexstone Capital LlcPassive (13G)Feb 4, 2026
- Adar1 Capital Management, LlcPassive (13G)Aug 14, 2025
- Nantahala Capital Management, LlcPassive (13G)Aug 14, 2025
- Lytton Laurence WPassive (13G)Aug 14, 2025
- Intracoastal Capital, LlcPassive (13G)Jul 8, 2025
- Hirschman OrinPassive (13G)Jan 27, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Longcor JarrodOfficer — Chief Operating Officer | May 7, 2026 | Buy | 8,680 | $2.88 |
| Caruso James VOfficer — Chief Executive Officer | May 7, 2026 | Buy | 8,680 | $2.88 |
| Neis JohnDirector | Dec 12, 2025 | Sell | 198 | $3.70 |
| Caruso James VOfficer — Chief Executive Officer | Jul 2, 2025 | Buy | 10,000 | $4.99 |
| Longcor JarrodOfficer — Chief Operating Officer | Jul 2, 2025 | Buy | 10,000 | $4.99 |
| Kolean Chad JOfficer — Chief Financial Officer | Jul 2, 2025 | Buy | 5,000 | $4.99 |
| Longcor JarrodOfficer — Chief Operating Officer | Jan 10, 2025 | Buy | 30,000 | $0.28 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 777,622 | 1.0 | +3288.2% |
| Apr 30, 2026 | 22,951 | 1.1 | -15.6% |
| Apr 15, 2026 | 27,204 | 1.3 | -55.5% |
| Mar 31, 2026 | 61,202 | 1.5 | +33.4% |
| Mar 13, 2026 | 45,874 | 1.0 | -49.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer changeMay 18, 2026
- Results of operationsMay 14, 2026
- Entered a material agreement · Unregistered equity sale · Other material eventMay 8, 2026
- Results of operationsMar 4, 2026
- Results of operationsNov 13, 2025
- Entered a material agreement · Results of operations · Unregistered equity sale · Modified shareholder rights · Other material eventOct 10, 2025
- Regulation FD disclosure · Other material eventOct 6, 2025
- Results of operationsAug 14, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- S-1/AFORM S-1/AMay 29, 2026
- DEFA14AMay 28, 2026
- DEF 14AMay 28, 2026
- S-1FORM S-1May 19, 2026
- PRE 14AMay 18, 2026
- 8-KFORM 8-KMay 18, 2026
- 8-KFORM 8-KMay 14, 2026
- 10-QMay 14, 2026
- 4OWNERSHIP DOCUMENTMay 11, 2026
- 4OWNERSHIP DOCUMENTMay 11, 2026
- SCHEDULE 13GMay 11, 2026
- 8-KFORM 8-KMay 8, 2026
- 424B5May 6, 2026
- 10-K/AApr 30, 2026
- 8-KFORM 8-KMar 4, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.